Announcement • Apr 29
Arecor Therapeutics plc, Annual General Meeting, May 28, 2026 Arecor Therapeutics plc, Annual General Meeting, May 28, 2026. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom New Risk • Apr 17
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 125% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (UK£1.7m revenue, or US$2.3m). Market cap is less than US$100m (UK£24.9m market cap, or US$33.7m). New Risk • Apr 14
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: UK£1.7m (US$2.3m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (UK£1.7m revenue, or US$2.3m). Market cap is less than US$100m (UK£24.9m market cap, or US$33.8m). New Risk • Apr 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£24.4m market cap, or US$32.8m). Announcement • Mar 30
Arecor Therapeutics plc to Report Fiscal Year 2025 Results on Apr 13, 2026 Arecor Therapeutics plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Apr 13, 2026 Board Change • Oct 15
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Non-Executive Chairman Andy Richards is the most experienced director on the board, commencing their role in 2016. Independent Non-Executive Director Jeremy Lewis Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 28
First half 2025 earnings released: UK£0.066 loss per share (vs UK£0.15 loss in 1H 2024) First half 2025 results: UK£0.066 loss per share (improved from UK£0.15 loss in 1H 2024). Revenue: UK£2.00m (flat on 1H 2024). Net loss: UK£2.51m (loss narrowed 46% from 1H 2024). Revenue is expected to decline by 69% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 12%. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Price Target Changed • Sep 25
Price target increased by 7.0% to UK£3.20 Up from UK£2.99, the current price target is an average from 3 analysts. New target price is 270% above last closing price of UK£0.86. Stock is up 28% over the past year. The company posted a net loss per share of UK£0.31 last year. New Risk • Sep 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£9.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£9.2m free cash flow). Earnings have declined by 22% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£27.4m market cap, or US$36.8m). Announcement • Sep 24
Arecor Therapeutics plc to Report First Half, 2025 Results on Sep 25, 2025 Arecor Therapeutics plc announced that they will report first half, 2025 results on Sep 25, 2025 Buy Or Sell Opportunity • Sep 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 54% to UK£0.67. The fair value is estimated to be UK£0.55, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years, while earnings per share has been flat. Announcement • Jul 16
Arecor Establishes New Scientific Advisory Board Arecor Therapeutics plc announced the formation of its new Scientific Advisory Board of internationally recognised experts in the fields of oral drug delivery and peptide therapeutics. Members of the Arecor Scientific Advisory Board include: David Brayden, PhD, is a Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and a Senior Fellow of the UCD Conway Institute. His research focuses on oral peptide delivery and nanomedicines, with over 300 research publications and 12 patents in these areas. He is an elected Fellow of both the Controlled Release Society and the American Association of Pharmaceutical Scientists, and is an elected member of the Royal Irish Academy. Dr. Brayden is co-lead PI on the Research Ireland Centre for Medical Devices (CURAM) and current coordinator of BUCCAL-PEP, an EU Horizon Europe grant on buccal administration of peptides. He serves as Chief Editor of "Frontiers in Drug Delivery" and was appointed by Ireland's Minister of Health as Chairperson to the National Research Ethics Committees on Clinical Trials (D). Dr. Brayden obtained his PhD from the University of Cambridge, followed by a postdoctoral fellowship at Stanford University, CA, USA, before spending 10 years at Elan Biotechnology Research. Randy Mrsny, PhD, is Professor of Drug Delivery at the University of Bath, where his research examines mechanisms controlling trans-epithelial migration and tight junction regulation, as well as the fate of biopharmaceuticals in subcutaneous and intramuscular spaces. He was the Founder and Chief Scientific Officer of Applied Molecular Transport (now Cyclo Therapeutics), which directed the advancement of technology utilising endogenous pathways for efficient epithelial transcytosis. His career includes leadership roles at ALZA Corporation, Genentech, and as founder of Trinity BioSystems and Unity Pharmaceuticals. Dr Mrsny has served as President of the Controlled Release Society, been selected to its College of Fellows, and received its Founders Award. He was selected for the Medicine Maker 100 power list in 2015 and 2016. Dr. Mrsny has a BSc in Biochemistry and Biophysics from the University of California and a PhD in Human Anatomy and Cell Biology from the UCD School of Medicine. Christopher Porter, PhD, is Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, with research focused on the absorption distribution and elimination profiles of drugs, as well as developing novel formulation approaches to optimise these profiles. He has published over 270 peer reviewed papers, his research programmes have attracted over $35m in funding, and is an inventor on more than 15 separate patent families. He is a Clarivate Analytics highly cited researcher, a fellow of the American Association of Pharmaceutical Scientists and an Editorial Board member for Molecular Pharmaceutics, Pharmaceutical Research and the Journal of Pharmaceutical Sciences. Dr. Porter obtained his BPharm and PhD in Pharmaceutics from the University of Nottingham. Buy Or Sell Opportunity • May 19
Now 25% overvalued Over the last 90 days, the stock has fallen 11% to UK£0.47. The fair value is estimated to be UK£0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years, while earnings per share has been flat. Announcement • May 07
Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025 Arecor Therapeutics plc, Annual General Meeting, Jun 02, 2025. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom New Risk • Apr 23
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£9.2m). Currently unprofitable and not forecast to become profitable next year (UK£6.2m net loss next year). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (UK£14.3m market cap, or US$19.1m). Reported Earnings • Apr 23
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: UK£0.31 loss per share (further deteriorated from UK£0.28 loss in FY 2023). Revenue: UK£5.05m (up 11% from FY 2023). Net loss: UK£10.2m (loss widened 20% from FY 2023). Revenue missed analyst estimates by 7.6%. Earnings per share (EPS) also missed analyst estimates by 3.3%. Revenue is forecast to stay flat during the next 2 years compared to a 13% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Announcement • Apr 10
Arecor Therapeutics plc to Report Fiscal Year 2024 Final Results on Apr 22, 2025 Arecor Therapeutics plc announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on Apr 22, 2025 Price Target Changed • Jan 11
Price target decreased by 7.1% to UK£3.38 Down from UK£3.64, the current price target is an average from 3 analysts. New target price is 478% above last closing price of UK£0.58. Stock is down 65% over the past year. The company is forecast to post a net loss per share of UK£0.30 next year compared to a net loss per share of UK£0.28 last year. New Risk • Jan 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.1m net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (UK£22.1m market cap, or US$27.0m). Announcement • Nov 19
Arecor Therapeutics plc Appoints David Ellam as Interim Chief Financial Officer Arecor Therapeutics plc announced the appointment of David Ellam as Interim Chief Financial Officer (CFO), effective immediately. David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, Silence Therapeutics and, more recently, Sixfold Bioscience. Early in his career, he qualified as an accountant at PwC, transitioning to a variety of financial and internal audit roles at companies including Smith & Nephew. Reported Earnings • Sep 27
First half 2024 earnings released: UK£0.15 loss per share (vs UK£0.15 loss in 1H 2023) First half 2024 results: UK£0.15 loss per share (further deteriorated from UK£0.15 loss in 1H 2023). Revenue: UK£2.00m (up 20% from 1H 2023). Net loss: UK£4.64m (loss widened 2.5% from 1H 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. Announcement • Sep 11
Arecor Therapeutics plc Presents Positive Data from Phase I Clinical Trial of Ultra-Concentrated, Ultra-Rapid Acting Insulins Arecor Therapeutics plc presents positive results from its Phase I clinical trial of the ultra-concentrated, ultra-rapid acting insulin candidate, AT278, in Type 2 diabetics with a high body mass index (BMI), at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid. AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements and to be a critical enabler of next-generation miniaturised and longer wear insulin pumps. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid® (100 U/mL), a currently available gold standard, rapid acting insulin, in 41 participants with Type 2 diabetes and a median BMI of 29.7 kg/m2. The trial was conducted in a glucose clamp setting at the Medical University of Graz and Joanneum Research in Austria, an internationally recognised centre of excellence in the field of diabetes research. The PK/PD profile for AT278 was accelerated compared withNovoRapid®. AT278 demonstrated a 1.7-fold (95% CI 1.32; 2.96) higher glucose-lowering effect within the first 60 minutes which was statistically superior toNovoRapid®(p< 0.0001). The glucose-lowering effect remained higher up to 2 hours post-dosing (treatment ratio [95% CI] 1.19 [1.02; 1.39]). AT278 showed a faster onset of glucose-lowering effect, with a 5-minute earlier onset of action and 25-minute earlier tEarly50% GIRmax thanNovoRapid®. It also showed a faster onset of insulin exposure compared with NovoRapid, witha 5-minute faster insulin appearance and 24-minute faster tEarly50% Cmax.Insulin exposure with AT278 was 1.5-fold higher within the first 60 minutes(95% CI 1.28; 1.71). The superior early glucose-lowering effect of AT278 was maintained when the population was divided into BMI subgroups. Both insulins were well tolerated. Adverse events were mostly mild to moderate and not related to the study drugs. Arecor is continuing to explore funding options for AT278, including but not limited to co-development arrangements, to conduct a clinical pump study to further demonstrate the potential of AT278 to disrupt the market by enabling the next generation of truly miniaturised, longer-wear insulin pumps, a key focus for patients, physicians and the industry. Announcement • Aug 02
Arecor Therapeutics plc to Report Q2, 2024 Results on Sep 23, 2024 Arecor Therapeutics plc announced that they will report Q2, 2024 results on Sep 23, 2024 Price Target Changed • Aug 02
Price target decreased by 9.0% to UK£4.18 Down from UK£4.59, the current price target is an average from 2 analysts. New target price is 351% above last closing price of UK£0.93. Stock is down 52% over the past year. The company posted a net loss per share of UK£0.28 last year. New Risk • Jul 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 30% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (UK£34.9m market cap, or US$44.9m). Announcement • Jul 24
Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million. Arecor Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.416654 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,955,847
Price\Range: £0.9
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 173,768
Price\Range: £0.9
Transaction Features: Regulation S; Subsequent Direct Listing New Risk • Jul 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£3.8m net loss in 2 years). Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (UK£36.0m market cap, or US$46.1m). New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (UK£1.9m net loss in 3 years). Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (UK£48.7m market cap, or US$62.0m). Announcement • Jun 08
Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024 Arecor Therapeutics plc, Annual General Meeting, Jun 28, 2024. Location: the offices of covington and burling llp, 22 bishopsgate, ec2n 4bq, london United Kingdom Major Estimate Revision • May 23
Consensus EPS estimates upgraded to UK£0.17 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from UK£7.57m to UK£7.49m. 2024 losses expected to reduce from -UK£0.215 to -UK£0.175 per share. Biotechs industry in the United Kingdom expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at UK£5.04. Share price rose 21% to UK£1.59 over the past week. Announcement • May 23
Arecor Therapeutics plc Announces Its Ultra-Concentrated, Ultra-Rapid Acting Insulins Arecor Therapeutics plc announced that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278, met all primary and secondary endpoints, and also demonstrated superiority to NovoRapid and Humulin R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI). AT278 (500 U/mL) is an ultra-concentrated, Ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements. In the double-blind, randomised, two-way crossover study, the pharmacokinetic (PK)/pharmacodynamic (PD) and safety profiles of a single subcutaneous (SC) dose of 0.5 U/kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.5 U/kg NovoRapid (100 U/mL), a currently available gold standard, rapid acting insulin treatment, in 39 participants with Type 2 diabetes within a BMI range of 25 and 39 kg/m2, in a euglycemic clamp setting. The PK/PD profile of 0.5 U/kg AT278 (500 U/mL) was also compared to a single SC dose of 0.5U/kg HumulinR U-500 (500 U/mL) in an open label manner. The trial met the primary endpoint of non-inferiority with respect to glucose lowering actions compared with NovoRapid.AT278 (500 U/mL) demonstrated a significantly accelerated (superior) early PK/PD profile compared to NovoRapid (100 U/mL), despite a 5-fold increase in concentration .AT278 (500 U/mL) demonstrated a significantly accelerated (superior) PK/PD profile compared to Humulin® R U-500 (500 U/mL), the only other insulin available at a concentration of 500 U/mL No safety signals were detected. Reported Earnings • May 17
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: UK£0.28 loss per share (improved from UK£0.32 loss in FY 2022). Revenue: UK£4.57m (up 90% from FY 2022). Net loss: UK£8.55m (loss narrowed 7.6% from FY 2022). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the United Kingdom. New Risk • May 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£2.1m net loss in 3 years). Revenue is less than US$5m (UK£3.4m revenue, or US$4.3m). Market cap is less than US$100m (UK£41.8m market cap, or US$53.0m). Price Target Changed • May 11
Price target increased by 12% to UK£5.08 Up from UK£4.55, the current price target is an average from 3 analysts. New target price is 272% above last closing price of UK£1.37. Stock is down 46% over the past year. The company is forecast to post a net loss per share of UK£0.24 next year compared to a net loss per share of UK£0.32 last year. Announcement • Apr 30
Arecor Therapeutics plc to Report Fiscal Year 2023 Results on May 07, 2024 Arecor Therapeutics plc announced that they will report fiscal year 2023 results on May 07, 2024 Announcement • Apr 24
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024 Arecor Therapeutics plc announced that Susan Lowther has decided to step down from her role as Company Secretary and as a Board Director, to pursue new opportunities. A search for Susan's successor is underway and her last day with Arecor is expected to be on the 22 July, to ensure an effective handover. Announcement • Oct 05
Arecor Therapeutics plc Provides Update on Progress of Second Phase I Clinical Study of Ultra-rapid, Ultra-Concentrated Insulin Candidate AT278 Arecor Therapeutics plc announced that, in line with the update provided within its Interim Results on 14 September, the Group has taken the decision to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278. The increase in the number of subjects within the study, from 32 to 42, will increase the power of the study and, in turn, increase the value of the results for patients with high insulin needs. Results are expected in early 2024. The trial is a double blind, randomized, crossover study comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile following a single subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL) in 42 people with Type 2 diabetes in a euglycemic clamp setting. In addition, the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R U500® will be evaluated in each of the participants. Major Estimate Revision • Sep 21
Consensus EPS estimates fall by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from UK£5.42m to UK£5.14m. Losses expected to increase from UK£0.17 per share to UK£0.23. Biotechs industry in the United Kingdom expected to see average net income growth of 8.5% next year. Consensus price target of UK£4.55 unchanged from last update. Share price rose 2.7% to UK£1.93 over the past week. Reported Earnings • Sep 17
First half 2023 earnings released: UK£0.15 loss per share (vs UK£0.16 loss in 1H 2022) First half 2023 results: UK£0.15 loss per share. Revenue: UK£1.67m (up 141% from 1H 2022). Net loss: UK£4.53m (loss widened 3.7% from 1H 2022). Revenue is forecast to grow 54% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom. Announcement • Aug 10
Arecor Therapeutics plc to Report First Half, 2023 Results on Sep 14, 2023 Arecor Therapeutics plc announced that they will report first half, 2023 results on Sep 14, 2023 Announcement • May 06
Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023 Arecor Therapeutics plc, Annual General Meeting, Jun 09, 2023, at 08:30 Coordinated Universal Time. Location: Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ London United Kingdom Major Estimate Revision • May 04
Consensus revenue estimates increase by 10% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from UK£4.94m to UK£5.46m. Forecast losses expected to reduce from -UK£0.20 to -UK£0.175 per share. Biotechs industry in the United Kingdom expected to see average net income decline 13% next year. Consensus price target broadly unchanged at UK£4.46. Share price was steady at UK£2.70 over the past week. Major Estimate Revision • Apr 27
Consensus EPS estimates upgraded to UK£0.20 loss, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from UK£5.39m to UK£4.94m. 2023 losses expected to reduce from -UK£0.33 to -UK£0.20 per share. Biotechs industry in the United Kingdom expected to see average net income decline 13% next year. Consensus price target of UK£4.39 unchanged from last update. Share price rose 3.8% to UK£2.70 over the past week. Reported Earnings • Apr 20
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: UK£0.32 loss per share (further deteriorated from UK£0.27 loss in FY 2021). Revenue: UK£2.40m (up 108% from FY 2021). Net loss: UK£9.26m (loss widened 50% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%. Revenue is forecast to grow 54% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Announcement • Jan 30
Aarecor Therapeutics plc Announces Publication of Phase I Data for AT278 in Diabetes Care Arecor Therapeutics plc announced that the American Diabetes Association journal, Diabetes Care, has published data from the Company's Phase I clinical trial of AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product candidate. The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People with Type 1 Diabetes', is now available online. In the Phase I clinical study in people with Type I diabetes, AT278 (500 U/mL) clearly demonstrated faster insulin absorption with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to gold-standard insulin NovoRapid® (100 U/mL) despite a 5-fold increase in concentration. AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market, and therefore, AT278 has the potential to be the first such product available to patients. It has the potential to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices. AT278 is also currently being investigated in a second Phase I trial in patients with Type 2 diabetes, to further explore the product's potential to disrupt the market as the first concentrated, yet rapid acting, insulin. The study initiated earlier this month and is expected to complete within fourth quarter of 2023. Price Target Changed • Jan 14
Price target decreased to UK£5.20 Down from UK£5.63, the current price target is provided by 1 analyst. New target price is 148% above last closing price of UK£2.10. Stock is down 48% over the past year. The company is forecast to post a net loss per share of UK£0.30 next year compared to a net loss per share of UK£0.27 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 14
Arecor Therapeutics plc to Report First Half, 2022 Results on Sep 05, 2022 Arecor Therapeutics plc announced that they will report first half, 2022 results on Sep 05, 2022 Reported Earnings • Apr 27
First half 2021 earnings: EPS exceeds analyst expectations First half 2021 results: UK£0.17 loss per share. Net loss: UK£3.11m (flat on 1H 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 18%. Over the next year, revenue is forecast to grow 3.7%, compared to a 15% growth forecast for the industry in the United Kingdom. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 31
Arecor Therapeutics plc to Report Fiscal Year 2021 Results on Apr 25, 2022 Arecor Therapeutics plc announced that they will report fiscal year 2021 results on Apr 25, 2022 Announcement • Jan 20
Arecor Therapeutics plc Commences the US Phase I Clinical Trial of Arecor's Lead Product, AT247 Arecor Therapeutics plc announced that it has commenced the US Phase I clinical trial of Arecor's lead product, AT247, an ultra-rapid insulin to be delivered by continuous subcutaneous infusion via insulin pump over a period of three days. The trial is a double blind, randomised, three-way crossover study comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of AT247 with Novo Nordisk's NovoRapid® and Fiasp®, two market-leading rapid acting insulin treatments in 24 participants with type I diabetes. It will be the first trial to investigate the product's potential when delivered by continuous subcutaneous infusion via insulin pump over a period of three days and follows a previous successful first-in-man clinical study. AT247, a novel proprietary formulation of insulin, aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes. AT247 has the potential to significantly improve post prandial glucose control so avoiding episodes of both hypo and hyperglycemia. In a European Phase I clinical study in Type I diabetic patients published in 2021, AT247 exhibited an earlier insulin appearance, exposure, and offset, with corresponding enhanced early glucose-lowering effect compared with NovoRapid® and Fiasp®. This new trial is targeted for completion in H2 2022 and is expected to provide additional evidence that AT247 has the potential to facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes. Announcement • Sep 21
Arecor Therapeutics plc Announces its Ultra-Concentrated Ultra-Rapid Acting Insulin, At278 Met all of its Primary and Secondary Endpoints with Positive Headline Results from the Phase I Clinical Trial Arecor Therapeutics plc announced that its ultra-concentrated ultra-rapid acting insulin, AT278 met all of its primary and secondary endpoints with positive headline results from the Phase I clinical trial. AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market and therefore AT278 has the potential to be the first such product available to patients. It has the potential to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices. In the double-blind, randomised, two-way crossover Phase I clinical study in 38 participants with Type I diabetes, the pharmacokinetics (PK), pharmacodynamics (PD) and safety of a single subcutaneous (SC) dose of 0.3 U/Kg AT278 (500 U/mL) were compared with those of a single SC dose of 0.3 U/Kg NovoRapid® (100 U/mL), a currently available gold standard rapid acting insulin treatment, in a euglycemic clamp setting. The trial met the primary endpoint of non-inferiority with respect to glucose lowering action as compared with NovoRapid®. In addition to meeting this primary endpoint, AT278 (500 U/mL) also demonstrated a significantly accelerated early PK/PD profile compared to NovoRapid® (100 U/mL), despite a 5-fold increase in concentration. No safety signals were detected. These Phase I clinical results in diabetes patients are clinically significant, and, as currently there are no concentrated (>200U/mL) rapid acting insulin products on the market, AT278 has the potential to be the first such product available to patients. AT278, enabled by Arecor's proprietary ArestatTM technology platform, has been developed to overcome the challenge whereby increasing the concentration of insulin typically results in a slower absorption and delayed glucose lowering profile. Board Change • Aug 24
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Chris Soden was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 08
Arecor Therapeutics plc Announces Formulation Study Collaboration with Par Sterile Products, LLC to Develop Stable Ready to Use Product Arecor Therapeutics plc announces that it has signed a formulation study agreement with Par Sterile Products, LLC. Under this agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, stable, single dose, Ready-to-Use ("RTU") formulation of one of Par's products for intravenous administration. The new product formulation supports safe medication practices and operational efficiency by eliminating the need for reconstitution. Par will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model (with associated potential milestone and royalty payments) to further develop and commercialise the product. Announcement • Jun 04
Arecor Therapeutics PLC has completed an IPO in the amount of £20.000001 million. Arecor Therapeutics PLC has completed an IPO in the amount of £20.000001 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,849,558
Price\Range: £2.26
Transaction Features: Direct Listing 